Ensitrelvir Prevents #COVID19 Infection as Post Exposure Prophylaxis
> Japan-based Shionogi presented results for its investigational antiviral, ensitrelvir, that demonstrated a 67% reduction in the risk of developing COVID-19 in uninfected individuals treated after exposure, compared to a placebo at day 10
